Senate Finance Committee Chairman Charles Grassley (R, Iowa) said the Food and Drug Administration (FDA) has taken important steps to inform consumers about the potential risk of vision loss associated with using drugs (sildenafil, tadalafil, and vardenafil) to treat erectile dysfunction (ED).
Last summer, the FDA approved updated labeling for these ED drugs to reflect some postmarketing reports of sudden vision loss attributed to nonarteritic ischemic optic neuropathy.
Mitka M. Scrutinizing ED Drugs. JAMA. 2006;295(2):152. doi:10.1001/jama.295.2.152-d